VanEck Pharmaceutical ETF
PPH
58 hedge funds and large institutions have $155M invested in VanEck Pharmaceutical ETF in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 9 closing their positions.
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
2% less funds holding
Funds holding: 59 → 58 (-1)
23.4% less ownership
Funds ownership: 69.14% → 45.74% (-23%)
24% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 21
31% less capital invested
Capital invested by funds: $225M → $155M (-$70.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $448K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$12.8M |
| 2 |
VF
Virtu Financial
New York
|
+$4.48M |
| 3 |
AL
Aspiriant LLC
Los Angeles,
California
|
+$3.58M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.6M |
| 5 |
Goldman Sachs
New York
|
+$875K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$59.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.47M |
| 3 |
Citigroup
New York
|
-$2.95M |
| 4 |
SB
Suntrust Banks
Atlanta,
Georgia
|
-$1.69M |
| 5 |
MIM
Macroview Investment Management
Bethesda,
Maryland
|
-$1.55M |
PPH Hedge Fund Activity: Q1 2016 in Review
58 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2016, worth a combined $155M — down 31% from $225M a quarter earlier.
Fund positioning in PPH was balanced in Q1 2016: 9 funds opened new positions, 9 closed out, 16 added to existing stakes and 21 trimmed.
The largest buyer was Harel Insurance Investments & Financial Services, opening a new position worth an estimated $12.8M. The largest seller was Migdal Insurance & Financial Holdings, exiting entirely with an estimated $59.1M sold.
- 58 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2016, down from 59 in Q4 2015.
- Funds reported $155M of VanEck Pharmaceutical ETF stock for Q1 2016, down 31% quarter-over-quarter.
- 9 funds opened new VanEck Pharmaceutical ETF positions in Q1 2016 and 9 closed out, a net change of 0 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2016 was Harel Insurance Investments & Financial Services, an estimated $12.8M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2016 was Migdal Insurance & Financial Holdings, an estimated $59.1M sold.
Based on aggregated 13F filings for Q1 2016.